Press Releases

This part of our website contains archival information which should not be considered current and may no longer be accurate. We do not intend, and assume no obligation, to update, correct or otherwise modify any of these press releases for events that occur subsequent to the original release date. Please view our more recent press releases in order to receive the most current information.

Media Contact:

Press Releases

AVEO Initiates Enrollment in Phase 3 Clinical Trial Evaluating Tivozanib in Advanced Renal Cell Cancer

February 22, 2010

AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering

December 16, 2009

AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting

November 17, 2009

AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors

September 16, 2009

AVEO Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

September 4, 2009

AVEO Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference

August 4, 2009

AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations

July 31, 2009

AVEO Pharmaceuticals to Present at IBC's New Frontiers in Cancer Drug Development Conference

July 30, 2009

OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

July 21, 2009

AVEO Pharmaceuticals Granted Patent for Protection of its Directed Complementation Technology

July 8, 2009

CEO of AVEO Pharmaceuticals Discusses Testing Stategies in a Life Sciences Report on NECN

June 18, 2009

AVEO Pharmaceuticals Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition

June 17, 2009

AVEO Pharmaceuticals to Present at the 8th Annual Needham & Company Life Sciences Conference

June 5, 2009

AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO

May 29, 2009

AVEO Pharmaceuticals to Present at Several Key Upcoming Medical and Industry Conferences

May 18, 2009

AVEO Pharmaceuticals' Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine

May 13, 2009

AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 in Preclinical Model of Liver Cancer

April 21, 2009

AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299)

April 19, 2009

Data on AVEO Pharmaceuticals' AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting

April 9, 2009

Breakthrough Preclinical Model for Human Cancer May Dramatically Improve Development of Effective Oncology Drugs; Data Published in PNAS

April 6, 2009

AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

March 26, 2009

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies

March 24, 2009

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies

March 23, 2009

AVEO Pharmaceuticals Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California

March 23, 2009

AVEO Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference

March 11, 2009

AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer

March 10, 2009

AVEO Pharmaceuticals to Present at the Barclays Global Healthcare Conference

March 6, 2009

AVEO Pharmaceuticals' Oral Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patents with Advanced Kidney Cancer

February 25, 2009

AVEO Initiates Phase 1b/2a Combination Trial of Novel, Triple VEGF Receptor Inhibitor - AV-951 in Advanced Breast Cancer

February 19, 2009

AVEO Pharmaceuticals to Present at Massachusetts Biotechnology Council

February 12, 2009

AVEO Pharmaceuticals Announces Oral Presentation of Data from AV-951 Phase 2 Clinical Trial at the 2009 Genitourinary Symposium

February 11, 2009

AVEO Pharmaceuticals to Present at 27th Annual J.P. Morgan Healthcare Conference

January 6, 2009

AVEO Pharmaceuticals to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference

November 12, 2008

AVEO to Present at First Annual Boston Biotech R&D Conference

October 20, 2008

AVEO to Present at JMP Securities Healthcare Conference

September 30, 2008

AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist

September 23, 2008

AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and other Gastrointestinal Cancers

August 25, 2008

Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement

July 22, 2008

AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell Carcinoma

May 29, 2008